Skip to main content

Alzheimer's Disease clinical trials at UCSD

17 in progress, 9 open to eligible people

Showing trials for
  • A Clinical Trial of AAV2-BDNF Gene Therapy in Early Alzheimer's Disease and Mild Cognitive Impairment

    open to eligible people ages 50-80

    This is a first-in-human clinical trial to test whether a protein administered into the brain continuously by gene therapy, Brain-Derived Neurotrophic Factor (BDNF), will slow or prevent cell loss in the brains of people affected by Alzheimer's disease and Mild Cognitive Impairment. The protein may also activate cells in the brain that have not yet deteriorated. Gene therapy refers to the use of a harmless virus to have brain cells make the potentially protective protein, BDNF.

    San Diego, California and other locations

  • A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease

    open to eligible people ages 55-80

    The primary purpose of this study is to evaluate the effect of JNJ-63733657 versus placebo on clinical decline as measured by the Integrated Alzheimer's Disease Rating Scale (iADRS), a composite of cognition and function.

    La Jolla, California and other locations

  • A Trial to Evaluate the Efficacy and Safety of PQ912 in Patients With Early AD

    open to eligible people ages 50-89

    This is a phase 2A multi-center, randomized, double blind, placebo-controlled, parallel group study of varoglutamstat, with a stage gate to phase 2B. In phase 2A there will be adaptive dosing evaluation of three dose levels with exposure to varoglutamstat or placebo for a minimum of 24 weeks, with preliminary evaluation of both cognitive function and pharmacodynamic changes on EEG spectral analysis in approximately 180 participants. In the event that the stage gate for phase 2B is reached, then phase 2B will assesses efficacy and longer-term safety in a larger study group, i.e., 414.

    La Jolla, California

  • Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3) Protocol

    open to eligible people ages 55-90

    Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging Initiative (ADNI) has been realized in informing the design of therapeutic trials in AD. ADNI3 continues the previously funded ADNI-1, ADNI-GO, and ADNI-2 studies that have been combined public/private collaborations between academia and industry to determine the relationships between the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of Alzheimer's disease (AD). The overall goal of the study is to continue to discover, optimize, standardize, and validate clinical trial measures and biomarkers used in AD research.

    La Jolla, California and other locations

  • An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects

    open to eligible people ages 50-80

    This study is being conducted to evaluate the safety and efficacy of ALZ-801 in Early Alzheimer's disease (AD) subjects with the APOE4/4 genotype. This is a double-blind, randomized trial with one dose of ALZ-801 compared to placebo.

    La Jolla, California and other locations

  • Biomarker Predictors of Memantine Sensitivity in Patients With Alzheimer's Disease

    open to eligible people ages 50-83

    The effects of the medication, memantine, on brain functions and the symptoms of Alzheimer's Disease will be tested

    San Diego, California

  • Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU001

    open to eligible people ages 18-80

    The purpose of this study is to assess the safety, tolerability, biomarker and cognitive efficacy of investigational products in subjects who are known to have an Alzheimer's disease-causing mutation by determining if treatment with the study drug slows the rate of progression of cognitive impairment and improves disease-related biomarkers.

    La Jolla, California and other locations

  • Down Syndrome Clinical Trials - Study of Alzheimer's Disease in Down Syndrome

    open to eligible people ages 25 years and up

    This is an observational, multi-center, longitudinal cohort study to characterize adults with DS ages 25 years and above enrolled at specialized care centers. The aim is to assess changes in cognition, behavior, function and health over approximately 32 months. Blood will be collected for the development of plasma AD biomarkers useful in the DS population.

    La Jolla, California and other locations

  • Safety, Tolerability, PK and PD of Posiphen® in Subjects With Early Alzheimer's Disease

    open to eligible people ages 55-85

    This study evaluates the safety and pharmacological effects of 3 different doses of Posiphen® when compared to a placebo, in adult male and female patients with early Alzheimer's disease (AD).

    La Jolla, California and other locations

  • A Study to Assess Safety and Target Engagement of E2814 in Participants With Mild to Moderate Cognitive Impairment Due to Dominantly Inherited Alzheimer's Disease

    Sorry, not currently recruiting here

    The primary objective of the study is to assess the safety and tolerability of intravenous (IV) infusions of E2814 in participants with dominantly inherited Alzheimer's disease (DIAD), and to evaluate target engagement (TE) of E2814 on microtubule binding region (MTBR)-tau species in cerebrospinal fluid (CSF) in participants with DIAD.

    La Jolla, California and other locations

  • A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205

    Sorry, in progress, not accepting new patients

    The primary objective is to evaluate the long-term safety and tolerability of aducanumab after a wash-out period imposed by discontinuation of feeder studies in participants who had previously received aducanumab (i.e. previously treated participants) or who had previously received placebo (i.e. treatment-naïve participants).

    La Jolla, California and other locations

  • An Extension Study of ABBV-8E12 in Early Alzheimer's Disease (AD)

    Sorry, in progress, not accepting new patients

    The purpose of this study is to assess the long-term safety and tolerability of ABBV-8E12 in subjects with early AD.

    La Jolla, California and other locations

  • Comparison of Two Group Wellness Interventions for Individuals With Neurologic Conditions and Their Support Persons

    Sorry, not yet accepting patients

    Approximately 5.3 million people live with a long-term disability resulting from a traumatic brain injury (TBI) and between 5-8% of those older than 60 suffer from Alzheimer's disease or other forms of dementia (ADRD). Consequences of these conditions can result in dramatic and persistent changes in functioning, impacting not only the patients, but also loved ones who become informal support persons. Many existing services help the family in the moment, but do not address long-term wellness. Thus, the purpose of this research study is to compare the effect of two different types of group wellness treatments for individuals with chronic mild TBI, moderate to severe TBI, and ADRD and their support persons.

  • Longitudinal Early-onset Alzheimer's Disease Study Protocol

    Sorry, not currently recruiting here

    The Longitudinal Early-onset Alzheimer's Disease Study (LEADS) is a non-randomized, natural history, non-treatment study designed to look at disease progression in individuals with early onset cognitive impairment. Clinical, cognitive, imaging, biomarker, and genetic characteristics will be assessed across three cohorts: (1) early onset Alzheimer's Disease (EOAD) participants, (2) early onset non-Alzheimer's Disease (EOnonAD) participants, and (3) cognitively normal (CN) control participants.

    La Jolla, California and other locations

  • Prazosin for Agitation in Alzheimer's Disease

    Sorry, in progress, not accepting new patients

    The study evaluates the effects of Prazosin on agitation in adults with Alzheimer's disease. Two thirds of the participants will participate in the medication portion, while one third will participate in the placebo portion

    San Diego, California and other locations

  • Salsalate in Patients Mild to Moderate Alzheimer's Disease

    Sorry, in progress, not accepting new patients

    The purpose of the study is to test the safety and tolerability of twice daily Salsalate in patients with mild to moderate Alzheimer's Disease. Half of the participants will receive Salsalate and half will receive placebo during the 1-year duration of the study.

    San Diego, California and other locations

  • Study of BHV-4157 in Alzheimer's Disease

    Sorry, in progress, not accepting new patients

    Preclinical models suggest that riluzole, the active metabolite of BHV-4157, may protect from AD-related pathology and cognitive dysfunction. Titrated dose of BHV-4157 to 280 mg, or placebo, taken orally once daily. Duration of treatment is 48 weeks. There is also a screening period of up to 42 days; and a 4-week post-treatment observation period.

    La Jolla, California and other locations

Last updated: